All In Biotech

Drug Trial Radar · NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

364

Planned (sponsor's estimate)

Start

Jan 25, 2022

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
SynthekineIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.

Conditions

  • Advanced Solid Tumor
  • Non Small Cell Lung Cancer
  • Untreated Advanced NSCLC
  • 1st Line NSCLC

Interventions

  • STK-012Drug

    Engineered Interleukin-2 (IL-2) selective for antigen activated T cells

  • pembrolizumab KEYTRUDA®Drug

    anti-PD-1 monoclonal antibody

  • pemetrexedDrug

    chemotherapy

  • carboplatinDrug

    chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Treatment emergent adverse events (TEAEs)Time frame: From 1st dose of study treatment through 90 days after last dose
  2. Phase 1a: Serious adverse events (SAEs)Time frame: From 1st dose of study treatment through 90 days after last dose
  3. Phase 1a: Dose limiting toxicities (DLTs)Time frame: Cycle 1, Days 1 through 21
  4. Phase 1a: DeathsTime frame: From 1st dose of study treatment until death, up to 4 years
  5. Phase 1b: TEAEs at the RP2DTime frame: From 1st dose of study treatment through 90 days after last dose
  6. Phase 1b: SAEs at the RP2DTime frame: From 1st dose of study treatment through 90 days after last dose
  7. Phase 1b: Deaths at the RP2DTime frame: From 1st dose of study treatment until death, up to 4 years
  8. Phase 2: Overall response rate (ORR) in Arm A versus Arm CTime frame: From randomization until disease progression or death, or the last evaluable assessment in the absence of progression, up to 4 years

Locations

60 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • Beverly Hills Cancer Center

    Beverly Hills, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Active not recruiting

  • Cedars Sinai

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Yale New Haven Hospital, Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Mayo Jacksonville

    Jacksonville, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Rochester

    Rochester, Minnesota · Recruiting

  • HealthPartners Cancer Center at Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Active not recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Active not recruiting

  • University Hospitals Cleveland

    Cleveland, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Terminated

  • Baptist Memorial Hospital Cancer Center

    Memphis, Tennessee · Active not recruiting

  • Sarah Cannon Research Institute - Nashville

    Nashville, Tennessee · Active not recruiting

  • Renovatio Clinical

    El Paso, Texas · Withdrawn

  • Oncology Consultants

    Houston, Texas · Recruiting

  • Renovatio Clinical

    The Woodlands, Texas · Withdrawn

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Active not recruiting

  • LTD High Technology Hospital Medcenter

    Batumi, Georgia · Recruiting

  • Caraps Medline, Ltd (JSC VIAN)

    Tbilisi, Georgia · Recruiting

  • Institute of Clinical Oncology (ICO)

    Tbilisi, Georgia · Recruiting

  • Israel Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia · Recruiting

  • START Dublin

    Dublin, Ireland · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.